Mixing Covishield & Covaxin Gives Better Immunity: ICMR

PUNE : A study by the Indian Council of Medical Research (ICMR) has found that mixing the two lead Covid-19 vaccines — Covishield and Covaxin — produces a better immune response than a same-dose schedule.

The research paper, which is yet to be peer-reviewed, says despite a weakening in antibody response after six months, those in the heterologous group — who were given one dose of Covishield and a second dose of Covaxin six weeks apart — showed a better immune response than those in the homologous group, people given either Covishield or Covaxin as both doses.

For the study, ICMR researchers analysed people in a village in Uttar Pradesh who were inadvertently given Covishield as their first dose and Covaxin as the second. Their immune responses were studied over a period of six months only after the completion of their vaccination schedule.

Two other groups were involved in the study — those who had taken two doses of either Covaxin or Covishield.

The researchers found a significant reduction in the IgG antibody titers targeting the receptor binding domain of the virus’ spike protein in all three groups. “But the mix-and-match group still had higher IgG antibody titers than the other two groups,” said Dr Samiran Panda, additional director-general of ICMR (New Delhi).

  • Related Posts

    WHO launches new primary health care course to strengthen health systems globally

    Health is a human right – yet not everyone can access the health services they need, when and where they need them, without financial hardship. Primary health care (PHC) provides…

    Ayurveda needs stronger evidence, safety monitoring for market adoption, says CCRAS

    Bengaluru: The Central Council for Research in Ayurvedic Sciences (CCRAS) has called for stronger scientific evidence, safety monitoring and translation of research into market-ready technologies to improve the credibility and…

    Leave a Reply

    Your email address will not be published. Required fields are marked *

    You Missed

    WHO launches new primary health care course to strengthen health systems globally

    WHO launches new primary health care course to strengthen health systems globally

    Ayurveda needs stronger evidence, safety monitoring for market adoption, says CCRAS

    Ayurveda needs stronger evidence, safety monitoring for market adoption, says CCRAS

    Yashoda Medicity Successfully Performs High-Risk Kidney Transplant in 28-Year- Old Woman

    Yashoda Medicity Successfully Performs High-Risk Kidney Transplant in 28-Year- Old Woman

    Avacta delivers two clinical stage peptide-drug conjugates to target delivery of toxic payloads into the tumour microenvironment

    Avacta delivers two clinical stage peptide-drug conjugates to target delivery of toxic payloads into the tumour microenvironment

    US FDA approves first gene therapy for paediatric patients with Sanfilippo syndrome type A

    US FDA approves first gene therapy for paediatric patients with Sanfilippo syndrome type A

    Technology and accessibility are key to growth of advanced treatment of heart diseases, says expert

    Technology and accessibility are key to growth of advanced treatment of heart diseases, says expert